Response to thalidomide is not associated with reduction of VEGF expression.

Immunohistochemical staining for VEGF in sections of decalcified human bones of SCID-hu hosts showing equal expression in CMC-treated (A,C) and thalidomide-treated (B,D) hosts inoculated with myeloma cells from patient 13; panels A and B show myeloma cells; panels C and D are bone marrow stromal cells.